Home>>Signaling Pathways>> Chromatin/Epigenetics>> RNA Polymerase>>GS-441524

GS-441524

Catalog No.GC46152

An antiviral nucleoside analog

Products are for research use only. Not for human use. We do not sell to patients.

GS-441524 Chemical Structure

Cas No.: 1191237-69-0

Size Price Stock Qty
50mg
$26.00
In stock
100mg
$34.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

GS-441524 is an antiviral nucleoside analog and the active metabolite of remdesivir. [1] GS-441524 is active against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome CoV (SARS-CoV) in infected primary human airway epithelial (HAE) cells (EC50s = 0.86 and 0.18 μM, respectively). It is cytoprotective against hepatitis C virus (HCV), yellow fever virus (YFV), dengue virus type 2 (DENV-2), influenza A, and parainfluenza 3 in cell-based assays (EC50s = 4.1, 11, 9.46, 27.9, and 1.71 μM, respectively).[2] Reference: [1]. Agostini, M.L., Andres, E.L., Sims, A.C., et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9(2), e00221-00218 (2018). [2]. Cho, A., Saunders, O.L., Butler, T., et al. Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg. Med. Chem. 22(8), 2705-2707 (2012).

Reviews

Review for GS-441524

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GS-441524

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.